BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Aguado C, Chara L, Antoñanzas M, Matilla Gonzalez JM, Jiménez U, Hernanz R, Mielgo-Rubio X, Trujillo-Reyes JC, Couñago F. Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy. World J Clin Oncol 2022; 13(5): 314-322 [PMID: 35662985 DOI: 10.5306/wjco.v13.i5.314]
URL: https://www.wjgnet.com/2218-4333/full/v13/i5/314.htm
Number Citing Articles
1
Linlin Ye, Yao Liu, Xuan Xiang, Zihao Wang, Wenbei Peng, Xiaoshan Wei, Siyu Zhang, Qianqian Xue, Qiong Zhou. Efficacy and safety of different cycles of neoadjuvant immunotherapy in resectable non-small cell lung cancer: A systematic review and meta-analysisHeliyon 2024; 10(11): e31549 doi: 10.1016/j.heliyon.2024.e31549
2
Rudolf M. Huber. Neoadjuvant therapy with immune checkpoint inhibitors in operable nonsmall cell lung cancerCurrent Opinion in Oncology 2024; 36(1): 29 doi: 10.1097/CCO.0000000000001002
3
Kun Pang, Zhen-Duo Shi, Liu-Ya Wei, Yang Dong, Yu-Yang Ma, Wei Wang, Guang-Yue Wang, Ming-Yang Cao, Jia-Jun Dong, Yu-Ang Chen, Peng Zhang, Lin Hao, Hao Xu, Deng Pan, Zhe-Sheng Chen, Cong-Hui Han. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockadeDrug Resistance Updates 2023; 66: 100907 doi: 10.1016/j.drup.2022.100907
4
Sukumar Kalvapudi, Yeshwanth Vedire, Sai Yendamuri, Joseph Barbi. Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challengesFrontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1286104
5
A. L. Akopov. The analysis of current international recommendations for the treatment of patients with stage III non-small cell lung cancerGrekov's Bulletin of Surgery 2024; 182(5): 68 doi: 10.24884/0042-4625-2023-182-5-68-75
6
Nong Yang, Hai‐Lin Yue, Bai‐Hua Zhang, Juan Chen, Qian Chu, Jian‐Xin Wang, Xiao‐Ping Yu, Lian Jian, Ya‐Wen Bin, Si‐Ye Liu, Jin Liu, Liang Zeng, Hai‐Yan Yang, Chun‐Hua Zhou, Wen‐Juan Jiang, Li Liu, Yong‐Chang Zhang, Yi Xiong, Zhan Wang. Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB–III non‐small cell lung cancer patients using radiomic featuresThoracic Cancer 2023; 14(28): 2869 doi: 10.1111/1759-7714.15052
7
Tetsuya Mitsudomi, Hiroyuki Ito, Morihito Okada, Shunichi Sugawara, Yutaka Shio, Keisuke Tomii, Jiro Okami, Noriaki Sakakura, Kaoru Kubota, Kazuya Takamochi, Shinji Atagi, Masahiro Tsuboi, Satoshi Oizumi, Norihiko Ikeda, Yasuhisa Ohde, Ives Ntambwe, Javed Mahmood, Junliang Cai, Fumihiro Tanaka. Neoadjuvant nivolumab plus chemotherapy in resectable non‐small‐cell lung cancer in Japanese patients from CheckMate 816Cancer Science 2024; 115(2): 540 doi: 10.1111/cas.16030
8
Robert W.C. Young, Gustavo R. Rodriguez, John Kucera, Daniel Carrera, Jared L. Antevil, Gregory D. Trachiotis. Molecular Markers, Immune Therapy, and Non-Small Cell Lung Cancer—State-of-the-Art Review for SurgeonsJournal of Laparoendoscopic & Advanced Surgical Techniques 2024; 34(9): 786 doi: 10.1089/lap.2024.0164
9
Kaushalendra Rathore. N1-positive non-small cell lung cancer: surgeons’ perspective before undertaking a major resectionIndian Journal of Thoracic and Cardiovascular Surgery 2024; 40(3): 353 doi: 10.1007/s12055-024-01724-7
10
Jennifer M. Pan, Ammara A. Watkins, Cameron T. Stock, Susan D. Moffatt-Bruce, Elliot L. Servais. The Surgical Renaissance: Advancements in Video-Assisted Thoracoscopic Surgery and Robotic-Assisted Thoracic Surgery and Their Impact on Patient OutcomesCancers 2024; 16(17): 3086 doi: 10.3390/cancers16173086